- Home
- WS vs MYGN Comparison
WS vs MYGN Comparison
Compare WS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WS
- MYGN
- Stock Information
- Founded
- WS 1955
- MYGN 1991
- Country
- WS United States
- MYGN United States
- Employees
- WS N/A
- MYGN N/A
- Industry
- WS
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WS
- MYGN Health Care
- Exchange
- WS Nasdaq
- MYGN Nasdaq
- Market Cap
- WS 2.2B
- MYGN 2.0B
- IPO Year
- WS N/A
- MYGN 1995
- Fundamental
- Price
- WS $31.06
- MYGN $12.57
- Analyst Decision
- WS Buy
- MYGN Hold
- Analyst Count
- WS 2
- MYGN 12
- Target Price
- WS $40.00
- MYGN $23.92
- AVG Volume (30 Days)
- WS 442.2K
- MYGN 1.0M
- Earning Date
- WS 12-18-2024
- MYGN 02-25-2025
- Dividend Yield
- WS 2.08%
- MYGN N/A
- EPS Growth
- WS 12.14
- MYGN N/A
- EPS
- WS 2.85
- MYGN N/A
- Revenue
- WS $3,289,800,000.00
- MYGN $823,600,000.00
- Revenue This Year
- WS N/A
- MYGN $13.73
- Revenue Next Year
- WS $0.86
- MYGN $4.34
- P/E Ratio
- WS $10.81
- MYGN N/A
- Revenue Growth
- WS N/A
- MYGN 12.15
- 52 Week Low
- WS $28.20
- MYGN $12.17
- 52 Week High
- WS $47.19
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- WS 38.39
- MYGN 32.55
- Support Level
- WS $29.94
- MYGN $12.17
- Resistance Level
- WS $31.06
- MYGN $15.08
- Average True Range (ATR)
- WS 1.08
- MYGN 0.80
- MACD
- WS 0.35
- MYGN -0.03
- Stochastic Oscillator
- WS 58.33
- MYGN 13.75
About WS Worthington Steel Inc.
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.